# MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

> **NCT00362024** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MK0952
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00362024
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362024, "MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00362024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*